Platinum-Mediated Nitrile-Hydroxylamine Coupling
CDCl3, δ: 1.01 (t, J ) 7.5 Hz, 6H, NCH2Me), 1.30 (t, J ) 7.5 Hz,
3H, CH2Me), 2.92-2.97 (m, 4H, NCH2Me and 2H, CH2Me), 8.14
(s, br, 1H, NH). 13C{1H} NMR in CDCl3, δ: 10.2 (CH3) and 26.4
(CH2)(Et), 11.7 (CH3) and 62.4 (CH2)(NEt), 175.7 (HNdC).
washed with diethyl ether (five 3-mL portions) to remove the excess
of the hydroxylamine. Yields are 80-90%, based on Pt.
[Ph3PCH2Ph][PtCl3{NHdC(Et)ONMe2}] (5). Anal. Calcd for
C30H34N2Cl3OPPt: C, 46.73; H, 4.44; N, 3.63%. Found: C, 46.53;
H, 4.54; N, 3.43%. FAB+-MS, m/z: 353 [Mcation], 262 [Mcation
-
cis-[PtCl2{NHdC(Et)ONEt2}2] (cis-2). Anal. Calcd for C14H32N4-
Cl2O2PPt: C, 30.33; H, 5.82; N, 10.11%. Found: C, 43.79; H, 4.31;
N, 3.24%. FAB-MS, m/z: 554 [M]+, 519 [M - Cl]+, 483
[M - 2Cl]+. IR spectrum (selected bands), cm-1: 3189 m-w
ν(N-H), 1661 s ν(CdN), 1438 m ν(CdC). 1H NMR spectrum in
CDCl3, δ: 1.01 (t, J ) 7.5 Hz, 6H, NCH2Me), 1.30 (t, J ) 7.5 Hz,
3H, CH2Me), 2.92-2.97 (m, 4H, NCH2Me and 2H, CH2Me), 8.14
(s, br, 1H, NH). 13C{1H} NMR in CDCl3, δ: 10.2 (CH3) and 26.4
(CH2)(Et), 11.7 (CH3) and 62.4 (CH2)(NEt), 175.7 (HNdC).
CH2Ph]. FAB- -MS, m/z: 417 [Manion], 347 [Manion - 2Cl]. IR
spectrum (selected bands), cm-1
:
3225 mw ν(N-H), 1652 s
ν(CdN), 1438 s ν(CdC), 1111 s ν(P-C), 750 s δ(C-H). 1H NMR
spectrum in CDCl3, δ: 1.14 (t, J ) 7.5 Hz, 3H, CH2Me), 2.82
(q, J ) 7.5 Hz, 2H, CH2Me), 3.09 (s, 3H, NMe), 4.91
2
(d, JPH ) 13.8 Hz, 2H, PCH2Ph), 6.97-7.29 and 7.53-7.74
(m, CH, Ph), 8.20 (s, br, 1H, NH). 13C{1H} NMR spectrum in
CDCl3, δ: 10.2 (CH3), 21.1(CH2)(Et), 30.8 (CH2, 1JPC ) 47.7 Hz,
PCH2Ph), 47.2 (Me, NMe), 116.6, 117.7, 126.7, 128.5, 128.8, 130.1,
130.2, 131.2, 134.1, and 135.0 (aryls), 176.5 (HNdC). 31P{1H}
NMR in CDCl3, δ: 23.2.
trans-[PtCl2{NHdC(Et)ON(CH2Ph)2}2] (trans-3). Anal. Calcd
for C34H40N4Cl2O2Pt: C, 50.87; H, 5.02; N, 6.98%. Found: C,
50.00; H, 5.02; N, 6.83%. FAB-MS, m/z: 641 [M]+, 569
[M - 2Cl]+. IR spectrum (selected bands), cm-1
: 3197 s
[Ph3PCH2Ph][PtCl3{NHdC(Et)ONEt2}] (6). Anal. Calcd for
ν(N-H), 1658 vs ν(CdN), 1435 m ν(CdC), 754 s δ(C-H).
1H NMR spectrum in CDCl3, δ: 1.02 (t, J ) 7.5 Hz, 3H, CH2Me),
2.75 (q, J ) 7.5 Hz, 2H, CH2Me), 3.98 and 4.06 (d, J ) 13.2 Hz,
4H, CH2Ph), 7.27-7.39 (m, 5H, CH, Ph), 8.10 (s, br, 1H, NH).
13C{1H} NMR in CDCl3, δ: 10.0 (CH3) and 25.8 (CH2)(Et), 62.4
(CH2, NCH2C6H5), 128.3, 128.7, 129.7, and 134.0 (aryls), 174.0
(HNdC).
C32H38N2Cl3OPPt: C, 48.10; H, 4.79; N, 3.51%. Found: C, 48.01;
H, 4.78; N, 3.41%. FAB+-MS, m/z: 353 [Mcation], 262 [Mcation
-
CH2Ph]. FAB- -MS, m/z: 410 [Manion - Cl], 339 [Manion - 3Cl].
IR spectrum (selected bands), cm-1: 3220 m-w ν(N-H), 1663 s
ν(CdN), 1437 s ν(CdC), 1111 s ν(P-C), 748 m δ(C-H). 1H NMR
spectrum in CDCl3, δ: 1.14 (t, J ) 7.5 Hz, 6H, NCH2Me), 1.24
(t, J ) 7.5 Hz, 3H, CH2Me), 2.96 (q, J ) 7.5 Hz, 4H, NCH2Me),
2
3.11 (q, J ) 7.5 Hz, 2H, CH2Me), 5.00 (d, JPH ) 13.5 Hz, 2H,
cis-[PtCl2{NHdC(Et)ON(CH2Ph)2}2] (cis-3). Anal. Calcd for
C34H40N4Cl2O2Pt: C, 50.87; H, 5.02; N, 6.98%. Found: C, 50.00;
H, 5.02; N, 6.83%. FAB-MS, m/z: 641 [M]+, 569 [M - 2Cl]+. IR
PCH2Ph), 7.05-7.82 (m, CH, Ph), 8.15 (s, br, 1H, NH). 13C{1H}
NMR spectrum in CDCl3, δ: 10.9 (CH2Me), 11.7 (NCH2Me), 24.1
1
spectrum (selected bands), cm-1
: 3197 s ν(N-H), 1658 vs
(CH2Me), 31.5 (CH2, JPC ) 47.6 Hz, PCH2Ph), 52.9 (NCH2Me),
1
116.8, 117.9, 128.4, 128.8, 130.4, 131.6, 134.4, 135.0 (Ph), 177.6
(HNdC). 31P{1H} NMR in CDCl3, δ: 28.4.
[Ph3PCH2Ph][PtCl3{NHdC(Et)ON(CH2Ph)2}] (7). Anal. Cal-
cd for C42H42N2Cl3OPPt: C, 54.64; H, 4.59; N, 3.03%. Found: C,
54.54; H, 4.57; N, 3.00%. FAB+-MS, m/z: 353 [Mcation], 262 [Mcation
- CH2Ph]. FAB- -MS, m/z: 569 [Manion], 534 [Manion - Cl]. IR
ν(CdN), 1435 m ν(CdC), 754 s δ(C-H). H NMR spectrum in
CDCl3, δ: 0.86 (t, J ) 7.5 Hz, 3H, CH2Me), 1.93 (q, J ) 7.5 Hz,
2H, CH2Me), 3.94 and 4.02 (m, J ) 12.6 Hz, 4H, CH2Ph), 7.27-
7.30 (m, 5H, Ph), 8.15 (s, br, 1H, NH). 13C{1H} NMR in CDCl3,
δ: 9.7 (CH3) and 25.3 (CH2)(Et), 61.8 (CH2, NCH2C6H5), 128.3,
128.7, 129.7, and 134.0 (aryls), 174.0 (HNdC).
spectrum (selected bands), cm-1
: 3222 mw ν(N-H), 1664 s
trans-[PtCl2{NHdC(Et)ON(CH2C6H4Cl-p)2}2] (trans-4). Anal.
Calcd for C34H36N4Cl6O2Pt: C, 43.42; H, 3.86; N, 5.96%. Found:
C, 43.24; H, 4.20; N, 5.89%. FAB-MS, m/z: 942 [M + 2H], 867
[M - 2Cl - H], 604 [M - L + 2H]. (eluent CH2Cl2). IR spectrum
(selected bands), cm-1: 3274 mw ν(N-H), 1661 s ν(CdN), 1433
ν(CdN), 1437 s ν(CdC), 1111 s ν(P-C), 749 s δ(C-H). 1H NMR
spectrum in CDCl3, δ: 0.85 (t, J ) 7.5 Hz, 3H, CH2Me), 2.91
(q, J ) 7.5 Hz, 2H, CH2Me), 4.08 (s, 4H, NCH2Ph), 5.00
2
(d, JPH ) 13.5 Hz, 2H, PCH2Ph), 7.04 (m, 2H, ortho), 7.15
1
s ν(CdC). H NMR spectrum in CDCl3, δ: 1.02 (t, J ) 7.5 Hz,
(m, 2H) and 7.24 (m, 1H)(PCH2Ph), 7.30-7.42 (m, 10H, NCH2Ph),
7.58-7.70 (m, 12H) and 7.78 (m, 3H)(Ph), 8.20 (s, br, 1H, NH).
13C{1H} NMR in CDCl3, δ: 10.5 (CH3) and 24.0 (CH2)(Et), 31.5
3H, CH2Me), 2.74 (q, J ) 7.5 Hz, 2H, CH2Me), 3.94 and 4.03
(d, J ) 13.8 Hz, 4H, CH2C6H4Cl-p), 7.22 and 7.35 (d, J ) 7.5 Hz,
4H, aryl), 8.03 (s, br, 1H, NH).13C{1H} NMR in CDCl3, δ: 10.2
(CH3) and 25.8 (CH2)(Et), 61.8 (CH2, NCH2C6H4Cl-p), 128.5,
129.1, 131.3, 132.1, 132.3, and 134.4 (aryls), 174.2 (HNdC).
1
(CH2, JPC ) 47.7 Hz, PCH2Ph), 61.4 (CH2, NCH2Ph), 117.5
(Cipso, 1JPC ) 86.1 Hz, Ph), 126.9 (Cipso, 2JPC ) 8.9 Hz, PCH2Ph),
128.1 (CH, NCH2Ph), 128.5 (CHp, JPC ) 2.8 Hz, PCH2Ph), 128.8
(CH, NCH2Ph), 128.9 (CHm, JPC ) 3.4 Hz, PCH2Ph), 129.8 (CH,
cis-[PtCl2{NHdC(Et)ON(CH2C6H4Cl-p)2}2] (cis-4). Anal. Cal-
cd for C34H36N4Cl6O2Pt: C, 43.42; H, 3.86; N, 5.96%. Found: C,
43.24; H, 4.20; N, 5.89%. FAB-MS, m/z: 942 [M + 2H]+, 867 [M
- 2Cl - H]+, 604 [M - L + 2H]+. IR spectrum (selected bands),
NCH2Ph), 130.3 (CH, JPC ) 11.9 Hz, Ph), 131.6 (CHo, JPC
5.5 Hz, PCH2Ph), 133.6 (Cipso, NCH2Ph), 134.4 (CH, JPC
)
)
10.1 Hz, Ph), 135.0 (CHp, JPC ) 2.8 Hz, Ph), 176.3 (HNdC).
31P{1H} NMR in CDCl3, δ: 23.5.
1
cm-1: 3274 mw ν(N-H), 1661 s ν(CdN), 1433 s ν(CdC). H
NMR spectrum in CDCl3, δ: 0.94 (t, J ) 7.5 Hz, 3H, CH2Me),
2.14 (q, J ) 7.5 Hz, 2H, CH2Me), 3.96 (m, 4H, CH2C6H4Cl-p),
7.21-7.36 (m, 4H, aryl), 8.51 (s, br, 1H, NH). 13C{1H} NMR in
CDCl3, δ: 9.8 (CH3) and 25.6 (CH2)(Et), 61.0 (CH2, NCH2C6H4-
Cl-p), 128.8, 130.8, 131.2, 132.3, 132.4, and 134.3 (aryls), 173.3
(HNdC).
[Ph3PCH2Ph][PtCl3{NHdC(Et)ON(CH2C6H4Cl-p)2}] (8). Anal.
Calcd for C42H40N2Cl5OPPt: C, 50.85; H, 4.06; N, 2.82%. Found:
C, 50.83; H, 4.04; N, 2.78%. FAB+-MS, m/z: 353 [Mcation], 262
[Mcation - CH2Ph]. FAB- -MS, m/z: 602 [Manion], 533 [Manion
3Cl + H]. IR spectrum (selected bands), cm-1
3204 mw
-
:
ν(N-H), 1663 s ν(CdN), 1439 s ν(CdC), 1111 s ν(P-C), 750 m
δ(C-H). 1H NMR spectrum in CDCl3, δ: 0.85 (t, J ) 7.5 Hz, 3H,
CH2Me), 2.80 (q, J ) 7.5 Hz, 2H, CH2Me), 4.05 (s, 4H, CH2C6H4-
Addition of R2NOH to [Ph3PCH2Ph][PtCl3(EtCN)]. In a
typical experiment, I (0.10 g, 0.140 mmol) is suspended in
chloroform (10 mL) at 20-25 °C, the hydroxylamine (0.140 mmol)
is added, and the reaction mixture is left to stand on vigorous stirring
for 12 h at room temperature. The bright yellow-orange solution is
evaporated to dryness under a flow of N2 and the solid residue is
2
Cl-p), 5.00 (d, JPH ) 13.5 Hz, 2H, PCH2Ph), 7.07-7.82 and
(m, CH, aryl), 8.15 (s, br, 1H, NH). 13C{1H} NMR in CDCl3, δ:
1
11.5 (CH3) and 24.5 (CH2)(Et), 31.5 (CH2, JPC ) 47.7 Hz,
PCH2Ph), 62.0 (CH2, NCH2C6H4Cl-p), 117.3, 118.5, 127.3, 128.9,
Inorganic Chemistry, Vol. 44, No. 8, 2005 2951